Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
In this open-label, randomized, prospective clinical trial, newly-diagnosed AML patients will be randomized into 2 groups. In the experimental arm, patients receive DA induction regimen with intermediate dose of cytarabine. In the control arm, patients receive DA regimen with standard dose of cytarabine.The efficacy of induction therapy containing intermediate dose of cytarabine is evaluated and adverse events associated with treatment are recorded.The primary end point is overall survival.
Epistemonikos ID: 287f382664f81a5d5f5a189b5089fdc430d59b3b
First added on: May 20, 2024